About Us

We are applying our innovative technology platform to build a leading, fully integrated global biopharmaceutical company

We are applying our innovative technology platform to build a leading, fully integrated global biopharmaceutical company

Algorithm for product innovation

Our unique approach to product innovation focuses on identifying unmet medical needs where a clinically validated parent drug or pathway is suitable to our TransCon technologies. We call this our “algorithm.” It helps us select and advance product candidates for our ever-growing pipeline.

Leveraging this strategic approach, we currently have a pipeline of three independent endocrinology rare disease product candidates in clinical development and we are advancing oncology as a second therapeutic area of focus. We continue to expand into new therapeutic areas to address unmet patient needs.

Arrow graphic of 6 steps that contribute to our process to create higher value, lower risk pipeline of product candidates
Vector-Smart-Object-copy

Our vision is to create new therapies focused on making a meaningful difference in patients’ lives.

VISEN Pharmaceuticals

In 2018, VISEN Pharmaceuticals (known as VISEN) was formed by Ascendis Pharma with an investor syndicate led by Vivo Capital.

Focusing on endocrinology, VISEN has received exclusive rights to develop and commercialize Ascendis Pharma's endocrinology rare disease therapies, including TransCon hGH, TransCon PTH and TransCon CNP in Greater China.

VISEN is conducting a phase 3 clinical trial for TransCon hGH in pediatric GHD, and planning to initiate a phase 3 clinical trial for TransCon PTH in hypoparathyroidism, as well as a phase 2 trial for TransCon CNP in achondroplasia. The partnership is a key strategy to establish global reach.

Explore

You are about to access www.ascendispharma.us, which includes information intended for U.S. residents only. Click below to confirm.

Are you a U.S. resident?

If so, please confirm below to proceed to our U.S. website. If not, continue to our global website.